METHOD OF TREATING INFLUENZA A
Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.
1 . A method of treating influenza A virus infection in a patient, the method comprising administering to the patient at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin of at least one group 1 subtype and at least one group 2 subtype of influenza A virus.
2 . A method of reducing influenza A virus infection in a patient, the method comprising administering to the patient at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin of at least one group 1 subtype and at least one group 2 subtype of influenza A virus.
3 . A method of preventing influenza A virus infection in a patient, the method comprising administering to the patient at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin of at least one group 1 subtype and at least one group 2 subtype of influenza A virus.
4 . The method according to any of the preceding claims, wherein the anti-influenza A antibody or fragment thereof is administered at a dose of at least about 250 mg and up to about 3000 mg.
5 . The method according to any of the preceding claims, wherein the anti-influenza A antibody or fragment thereof is capable of neutralizing at least one group 1 subtype and at least one group 2 subtype of influenza A virus.
6 . The method according to any of the preceding claims, wherein administering includes parenteral administration.
7 . The method according to any of the preceding claims, wherein administering includes intravenous administration.
8 . The method according to claim 7 , wherein anti-influenza A antibody or fragment thereof is administered as a single dose.
9 . The method according to any of the preceding claims, wherein anti-influenza A antibody or fragment thereof is administered after the patient is exposed to influenza A virus, infected with influenza A virus, exhibits symptoms of influenza A virus infection, or a combination thereof.
10 . The method according to any of claims 1 - 8 , wherein anti-influenza A antibody or fragment thereof is administered before the patient is exposed to influenza A virus, infected with influenza A virus, exhibits symptoms of influenza A virus infection, or a combination thereof.
11 . The method according to any of claims 1 - 8 , wherein anti-influenza A antibody or fragment thereof is administered to a subject within 30 days of exposure, infection, symptom onset, or a combination thereof.
12 . The method according to any of the preceding claims, wherein anti-influenza A antibody or fragment thereof is capable of neutralizing one or more influenza A virus group 1 subtype selected from: H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, and variants thereof; and one or more influenza A virus group 2 subtypes selected from: H3, H4, H7, H10, H14 and H15 and variants thereof.
12 . The method according to any one of the preceding claims, wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs having an amino acid sequence at least 75% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs having amino acid sequence at least 75% identical to an amino acid sequence selected from an amino acid sequence shown in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
13 . The method according to any one of the preceding claims, wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs with an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs with an amino acid sequence selected from SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
14 . The method according any one of the preceding claims, wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 2 and a VL having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 7.
15 . The method according any one of the preceding claims, wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence shown in SEQ ID NO: 2 and a VL having an amino acid sequence shown in SEQ ID NO: 7.
16 . The method according to any of the preceding claims, wherein anti-influenza A antibody comprises MEDI8852.
17 . The method according to any of the preceding claims, wherein the antibody or fragment thereof is administered in combination with one or more small molecule antiviral medications.
18 . The method according to claim 17 , wherein the small molecule antiviral medication is selected from oseltamivir (TAMIFLU®), zanamivir (RELENZA®), amantadine and rimantadine.
19 . A composition for treating influenza A virus infection in a patient, the composition comprising anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin at least one group 1 subtype and at least one group 2 subtype of influenza A virus formulated for administering at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof to a patient.
20 . A composition for reducing influenza A virus infection in a patient, the composition comprising anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin at least one group 1 subtype and at least one group 2 subtype of influenza A virus formulated for administering at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof to a patient.
21 . A composition for preventing influenza A virus infection in a patient, the composition comprising anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin of at least one group 1 subtype and at least one group 2 subtype of influenza A virus formulated for administering at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof to a patient.
22 . The composition according to any of claims 19 - 21 , wherein anti-influenza A antibody or fragment thereof is capable of neutralizing one or more influenza A virus group 1 subtype selected from: H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, and variants thereof; and one or more influenza A virus group 2 subtypes selected from: H3, H4, H7, H10, H14 and H15 and variants thereof.
23 . The composition according to any of claims 19 - 22 , wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs having an amino acid sequence at least 75% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs having amino acid sequence at least 75% identical to an amino acid sequence selected from an amino acid sequence shown in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
24 . The composition according to any of claims 19 - 23 , wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs with an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs with an amino acid sequence selected from SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
25 . The composition according to any of claims 19 - 24 , wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 2 and a VL having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 7.
26 . The composition according to any of claims 19 - 25 , wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence shown in SEQ ID NO: 2 and a VL having an amino acid sequence shown in SEQ ID NO: 7.
27 . The composition according to any of claims 19 - 26 , wherein anti-influenza A anti-influenza A antibody comprises MEDI8852.
28 . The composition according to any of claims 19 - 27 , wherein the composition further comprises a pharmaceutically acceptable carrier.
29 . The composition according to any of claims 19 - 28 , wherein the composition further comprises one or more small molecule antiviral medications.
30 . The composition according to claim 29 , wherein the small molecule antiviral medications is selected from oseltamivir (TAMIFLU®), zanamivir (RELENZA®), amantadine and rimantadine.
31 . An article of manufacture comprising a container and a composition within the container, wherein the composition comprises anti-influenza A antibody or fragment thereof that is capable of binding to influenza A virus hemagglutinin of at least one group 1 subtype and at least one group 2 subtype of influenza A virus and instructions to administer of at least about 200 mg and up to about 3500 mg anti-influenza A antibody or fragment thereof to a patient.
32 . The article of manufacture according to claim 31 , wherein the label or package insert includes instructions to administer anti-influenza A antibody or fragment thereof at a dose of at least about 200 mg and up to about 3500 mg.
33 . The article of manufacture according to claim 31 or 32 , wherein anti-influenza A antibody or fragment thereof is capable of neutralizing one or more influenza A virus group 1 subtype selected from: H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, and variants thereof; and one or more influenza A virus group 2 subtypes selected from: H3, H4, H7, H10, H14 and H15 and variants thereof.
34 . The article of manufacture according to any of claims 31 - 33 , wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs having an amino acid sequence at least 75% identical to an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs having amino acid sequence at least 75% identical to an amino acid sequence selected from an amino acid sequence shown in SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
35 . The article of manufacture according to any of claims 31 - 34 , wherein anti-influenza A antibody or fragment thereof includes one or more heavy chain CDRs with an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5 and one or more light chain CDRs with an amino acid sequence selected from SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
36 . The article of manufacture according to any of claims 31 - 35 , wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 2 and a VL having an amino acid sequence with at least 75% identity to the amino acid sequence of SEQ ID NO: 7.
37 . The article of manufacture according to any of claims 31 - 36 , wherein anti-influenza A antibody or fragment thereof comprises a VH having an amino acid sequence shown in SEQ ID NO: 2 and a VL having an amino acid sequence shown in SEQ ID NO: 7.
38 . The article of manufacture according to any of claims 31 - 37 , wherein anti-influenza A antibody comprises MEDI8852.
39 . The article of manufacture according to any of claims 31 - 38 , further comprising one or more small molecule antiviral medications.
40 . The article of manufacture according to claim 39 , wherein the small molecule antiviral medications is selected from oseltamivir (TAMIFLU®), zanamivir (RELENZA®), amantadine and rimantadine.
41 . The article of manufacture according to any of claims 31 - 40 , wherein the composition further comprises a pharmaceutically acceptable carrier.